Literature DB >> 879898

Control of heparinization by activated clotting time during bypass with improved postoperative hemostasis.

J J Verska.   

Abstract

Heparin and protamine dosages monitored during open-heart operations by activated clotting time (ACT) have been reported to be superior to dosage schedules based on body weight or body surface area. To evaluate the automated ACT, 114 consecutive open-heart operations performed between October, 1974, and December, 1975, were studied. Fifty-eight operations prior to April, 1975, using a standard heparin-protamine protocol (Group I) were compared with 56 operations from April to December, 1975, monitored with an automated ACT (Group II). The two groups were similar with respect to surgical procedures, pump time, and perfusion techniques. The protamine/heparin ratio was 25% less in Group II compared with Group I, and the 12-hour postoperative blood loss was 48% less in Group II. The automated ACT is a reliable, rapid, and simple test that has resulted in improved hemostasis following cardiac operation.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 879898     DOI: 10.1016/s0003-4975(10)63728-9

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN: 0003-4975            Impact factor:   4.330


  8 in total

1.  Blood transfusion requirements in coronary artery surgery with and without the activated clotting time (ACT) technique.

Authors:  D U Preiss; H Schmidt-Bleibtreu; P Berguson; G Metz
Journal:  Klin Wochenschr       Date:  1985-03-15

2.  Clinical Evaluation of Measuring the ACT during Elective Cardiac Surgery with Two Different Devices.

Authors:  Florian Falter; Nabeel Razzaq; Martin John; Jens Fassl; Markus Maurer; Sean Ewing; Ross Hofmeyr
Journal:  J Extra Corpor Technol       Date:  2018-03

Review 3.  Use of the activated clotting time in anticoagulation monitoring of intravascular procedures.

Authors:  J Bowers; J J Ferguson
Journal:  Tex Heart Inst J       Date:  1993

4.  Risk Factors Associated with Difficult Reversal of Heparin by Protamine Sulfate in Cardiopulmonary Bypass: An Ignored Issue.

Authors:  Min Jung Ku; Su Wan Kim; Seogjae Lee; Jee Won Chang; Jonggeun Lee
Journal:  Korean J Thorac Cardiovasc Surg       Date:  2020-10-05

5.  Accuracy of point-of-care coagulation testing during cardiopulmonary bypass in a patient post COVID-19 infection.

Authors:  Nimrat Grewal; David Yousef; Meindert Palmen; Robert Klautz; Jeroen Eikenboom; Jeroen Wink
Journal:  J Cardiothorac Surg       Date:  2022-05-07       Impact factor: 1.522

6.  Activated clotting time systems vary in precision and bias and are not interchangeable when following heparin management protocols during cardiopulmonary bypass.

Authors:  Ian J Welsby; Elizabeth McDonnell; Habib El-Moalem; Mark Stafford-Smith; John G Toffaletti
Journal:  J Clin Monit Comput       Date:  2002-07       Impact factor: 2.502

7.  Use of activated clotting time for monitoring anticoagulation during cardiopulmonary bypass in infants and children with congenital heart disease.

Authors:  S Bert Litwin; Samir K. Mitra; Rochelle Von Colditz; John Von Colditz; Linda B. Hamilton; Terrance McManus; Hani G. Jume'an; Jack Lazerson
Journal:  Cardiovasc Dis       Date:  1981-09

Review 8.  Clinical pharmacokinetics of heparin.

Authors:  J W Estes
Journal:  Clin Pharmacokinet       Date:  1980 May-Jun       Impact factor: 6.447

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.